BrightPath Biotherapeutics Co.Ltd.

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs in Japan. Its pipeline includes BP2201, BP2202, and BP2301, all in Phase I clinical trials; BP2201 targets cancer antigens across various cancer types, BP2202 targets cancer, and BP2301 is for solid tumors, sarcoma, and gynecological cancers. Preclinical candidates include BP1200 (targeting CD73), BP1202 (targeting CD39), BP1210 (suppressing T cell cytotoxicity), BP1212 (inhibiting TIM-3 and CD39), BP1209 (targeting tumor-specific neoantigens), and BP1223 (targeting blood cancers). Formerly known as GreenPeptide Co., Ltd., the company changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017; it was incorporated in 2003 and is headquartered in Kawasaki, Japan.